ClinicalTrials.gg
TerminatedNCT02895529Updated May 6, 2019

A Study Comparing the Efficacy of Intravenous Followed by Oral Itraconazole With Intravenous Caspofungin For Empiric Antifungal Therapy in Neutropenic Participants With Hematological Malignancy

A Phase 4 interventional study of Itraconazole and Caspofungin in Hematologic Neoplasms, sponsored by Xian-Janssen Pharmaceutical Ltd.. Terminated at 12 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-05-06.

Sponsored by Xian-Janssen Pharmaceutical Ltd. (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment

Why this study was terminated
Study is a commitment for license renew, we target on Apr19 submission, considering timeline, a cut off should be scheduled in Apr18.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
61
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Hematologic Neoplasms by Johnson & Johnson — 2 open to participants now, 5 under way, none of them phase 3. Hematologic Neoplasms · Johnson & Johnson.

Started
2016
the only one that year
Phase 4
Only one
of the 14
Registered
8th of 14
by date

Among the 14 studies in Hematologic Neoplasms by Johnson & Johnson, this one is the only one that started in 2016, is the only one in phase 4, and was the 8th registered.

Hematologic Neoplasms

1,445 studies on the registry are indexed under Hematologic Neoplasms; 421 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

2 of the 14 studies in Hematologic Neoplasms by Johnson & Johnson are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 314 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Hematologic Neoplasms by Johnson & Johnson, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the hypothesis that the efficacy of intravenous (IV) itraconazole followed by oral itraconazole is non-inferior to that of intravenous caspofungin as empiric therapy for suspected fungal infection participants with fever and neutropenia.

03

Conditions studied

  • Hematologic Neoplasms
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be hospitalized with hematologic treated by myelosuppressive therapy and/or Hematopoietic stem cell transplantation
  • Participant must have a diagnosis of neutropenia with \< 500/microliters (mcL) (0.5 × 10\^9/ liters [L]) for at least 96 hours at screening
  • Participant must have a diagnosis of fever and meet the following criteria: 1) Oral/rectal temperature greater than or equal to (>=) 38 degree celsius or axillary temperature (>=) 37.5 degree celsius and is not considered related to blood products transfusion or drug fever, 2) Not responding to broad-spectrum gram-positive and gram-negative antibiotics for 4-7 days with or without signs and symptoms that potentially attributable to deep fungal infection and 3) Defervescence within 3 days after the first broad-spectrum antibiotics but recurrence afterwards.
  • A woman of must have a negative serum (beta human chorionic gonadotropin [b hCG]) and pregnancy test at screening
  • A woman must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study period and until the menstrual period following the end of study treatment

Exclusion criteria

Exclusion Criteria:

  • Is concomitantly using other systematic antifungal drugs as empirical treatment
  • Has evidence of inadequately managed bacterial infection
  • Is currently receiving any Cytochrome P450 3A4 ()-metabolized/P-glycoprotein-transported drugs (including but not limited to cisapride, pimozide, quinidine, dofetilide, levacetylmethadol, terfenadine, astemizole, mizolastine, bepridil, sertindole, 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMG-CoA reductase) inhibitor [for example, simvastatin, lovastatin], oral midazolam, triazolam, ergot alkaloids [eg, dihydroergotamine, ergonovine, ergotamine, methylergonovine] and nisoldipine) that should be prohibited in this study
  • Has known allergy, intolerance or to azole and echinocandin antifungals or its
  • Has a to the use of sodium chloride injection
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
61 participants (actual)

Study arms

  • Experimental
    Itraconazole

    Drug: Itraconazole

  • Active comparator
    Caspofungin

    Drug: Caspofungin

Interventions

  • Participants will receive 200 milligram (mg) of itraconazole intravenously (IV) twice daily on Day 1 and Day 2, followed by 200 mg once daily through Day 14. From Day 15 to Day 28, participants will receive 200 mg (20 milliliters \[mL\]) of itraconazole oral solution orally twice daily. Participants, who are not suitable for oral administration of itraconazole based on the investigator's judgment, will receive 200 mg of itaconazole IV once daily from Day 15 to Day 28.

  • Participants will receive 70 mg of caspofungin IV once daily on Day 1 followed by 50 mg IV infusion once daily thereafter through Day 28.

06

What researchers measure

Primary outcomes

  1. Response Rate Measured by the Percentage of Participants That Achieve all of the Following 5 Composite Endpoints

    Response rate in each of the 2 treatment groups will be measured by the percentage of participants that achieve all of the following 5 composite endpoints: 1) survival for 7 days after completion of treatment, 2) absence of breakthrough invasive fungal infection during the study drug administration and within the first 7 days after completion of treatment, 3) successful treatment of baseline fungal infection, 4) defervescence and 5) no premature withdrawal from the study due to drug-related toxicity or lack of efficacy.

    Time frame: Up to 36 days

Secondary outcomes

  1. Percentage of Participants With Survival for 7 Days After Completion of Treatment

    Time frame: Up to 36 days

  2. Percentage of Participants With Absence of Breakthrough Invasive Fungal Infection

    Absence of breakthrough invasive fungal infection is defined as the clinically or/and microbiologically documented fungal infection with an onset on or after day 3 of the study treatment during the study drug administration and within the first 7 days after completion of treatment.

    Time frame: Day 3 up to Day 28 (End of treatment [EoT]) and within 7 days after EoT (Day 29 up to Day 35)

  3. Percentage of Participants With Successful Treatment of Baseline Fungal Infection

    Successful treatment of baseline fungal infection is defined as the clinically and microbiologically documented fungal infection with an onset within screening to 2 days after the study treatment.

    Time frame: Screening up to Day 3

  4. Percentage of Participants With Defervescence During the Period of Neutropenia

    Defervescence is defined as oral/rectal temperature less than (\<) 38 degree celsius or axillary temperature (\<) 37.5 degree celsius for over 48 hours) during the period of neutropenia.

    Time frame: Up to 36 days

  5. Percentage of Participants With No Premature Withdrawal From the Study due to Drug-related Toxicity or Lack of Efficacy

    Time frame: Up to 36 days

  6. Response Rate Measured by the Percentage of Participants That Achieve all of the Following 5 Composite Endpoints With Oral Administration of Itraconazole

    Response rate will be measured by the percentage of participants (who received oral administration of itraconazole) that achieve all of the following 5 composite endpoints: 1) survival for 7 days after completion of treatment, 2) absence of breakthrough invasive fungal infection during the study drug administration and within the first 7 days after completion of treatment, 3) successful treatment of baseline fungal infection, 4) defervescence and 5) no premature withdrawal from the study due to drug-related toxicity or lack of efficacy.

    Time frame: Up to 36 days

07

Study locations

12 sites
  • Beijign, China
  • Beijing, China
  • Changchun, China
  • Changzhou, China
  • Fuzhou, China
  • Guangzhou, China
  • Guiyang, China
  • Hefei, China
  • Shanghai, China
  • Suzhou, China
  • Tianjin, China
  • Zhengzhou, China
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2016 to primary completion in May 2018, 17 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2016
First posted
Sep 9, 2016
StartActual
Nov 30, 2016
Primary completionActual
May 2, 2018
CompletionActual
May 2, 2018
Last update
May 6, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02895529
Responsible party
Sponsor
First posted
Sep 9, 2016
Start date
Nov 30, 2016
Primary completion
May 2, 2018
Completion
May 2, 2018
Last update
May 6, 2019

Study contacts

Xian-Janssen Pharmaceutical Ltd., China Clinical Trial
study director · Xian-Janssen Pharmaceutical Ltd.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Itraconazole

Start the discussion